NewGenIvf Group (NIVF) CEO awarded 56,851 low-price stock options

Q: What did NewGenIvf Group (NIVF) report in this Form 4 filing?

NewGenIvf Group reported a grant of 56,851 stock options to its Chairman & CEO, Siu Wing Fung Alfred, under the 2024 Share Incentive Plan. These options allow him to acquire Class B Ordinary Shares at a nominal exercise price of US$0.0001 per share.

Q: Who received stock options in NewGenIvf Group (NIVF) and in what amount?

Chairman & CEO Siu Wing Fung Alfred received 56,851 stock options to acquire Class B Ordinary Shares. The grant is part of NewGenIvf Group’s 2024 Share Incentive Plan and is held directly, as reflected in the Form 4 insider filing.

Q: What is the exercise price of the NewGenIvf Group (NIVF) stock options granted?

The granted stock options have an exercise price of US$0.0001 per share . This very low strike price means the CEO can acquire Class B Ordinary Shares at a nominal cost when options vest, according to the 2024 Share Incentive Plan and option agreement.

Q: How do the NewGenIvf Group (NIVF) CEO’s stock options vest?

The options vest over time: 5,685 options on 4 June 2026 , then 1,462 options on the 4th of each month from July 2026 through April 2029, and 1,458 options on 4 May 2029 , creating a structured, long-term vesting schedule.

Q: When do the granted NewGenIvf Group (NIVF) stock options expire?

The CEO’s stock options expire on 4 May 2033 , subject to earlier termination under the option agreement and plan terms. After this date, any unexercised options lapse and can no longer be used to acquire Class B Ordinary Shares of NewGenIvf Group.

Q: How many NewGenIvf Group (NIVF) options does the CEO hold after this grant?

Following this grant, the CEO holds 56,881 stock options directly, as shown in the Form 4. This figure reflects his total derivative position in these options immediately after the award was made under the 2024 Share Incentive Plan.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

NewGenIvf Group Ltd Chairman & CEO Siu Wing Fung Alfred received a grant of stock options to acquire 56,851 Class B Ordinary Shares at an exercise price of US$0.0001 per share under the company’s 2024 Share Incentive Plan.

The options vest monthly from 4 June 2026 through 4 May 2029, starting with 5,685 options and then 1,462 options on most monthly vesting dates, with 1,458 options vesting in the final tranche. The options expire on 4 May 2033, and following this grant he holds 56,881 stock options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Siu Wing Fung Alfred

Role Chairman & CEO

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (Right to Buy)	56,851	$0.00	--

Holdings After Transaction: Stock Options (Right to Buy) — 56,881 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Options granted: 56,851 options Exercise price: US$0.0001 per share First vesting tranche: 5,685 options +4 more

7 metrics

Options granted 56,851 options Stock options to acquire Class B Ordinary Shares

Exercise price US$0.0001 per share Strike price for granted stock options

First vesting tranche 5,685 options Vesting on 4 June 2026

Monthly vesting tranches 1,462 options On 4th of each month from July 2026 to April 2029

Final vesting tranche 1,458 options Vesting on 4 May 2029

Options expiration date 4 May 2033 Option term end date, subject to earlier termination

Options held after grant 56,881 options Total stock options directly held post-transaction

Key Terms

Stock Options (Right to Buy), Class B Ordinary Shares, 2024 Share Incentive Plan, Employee Stock Option Agreement, +1 more

5 terms

Stock Options (Right to Buy) financial

"security_title: "Stock Options (Right to Buy)""

Class B Ordinary Shares financial

"underlying_security_title: "Class B Ordinary Shares""

Class B ordinary shares are a type of ownership stake in a company that typically come with different voting rights or privileges compared to other share classes. For investors, they represent a way to hold part of the company’s value and influence its decisions, often with fewer voting rights than Class A shares. Understanding these shares helps investors assess their level of control and potential returns within a company.

Employee Stock Option Agreement financial

"and the Employee Stock Option Agreement, dated 4 May 2026"

Final Tranche financial

"and 1,458 options on 4 May 2029 (Final Tranche)"

Form 4 Insider Transactions: What Each Field Means →

05/06/2026 - 04:01 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Siu Wing Fung Alfred

(Last)

(First)

(Middle)

C/O 1/F, PIER 2, CENTRAL

(Street)

HONG KONG

(City)

(State)

(Zip)

HONG KONG

(Country)

2. Issuer Name and Ticker or Trading Symbol
NewGenIvf Group Ltd [ NIVF ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chairman & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Options (Right to Buy)	$0.0001	05/04/2026		A		56,851		⁽¹⁾	05/04/2033	Class B Ordinary Shares	56,851	$0	56,881	D

Explanation of Responses:

1. Reflects the grant of stock options to acquire 56,851 Class B Ordinary Shares of the Issuer at an exercise price of US$0.0001 per share, made pursuant to the Issuer's 2024 Share Incentive Plan and the Employee Stock Option Agreement, dated 4 May 2026, between the Issuer and the Reporting Person (the "Option Agreement"). The options vest as follows: 5,685 options on 4 June 2026 (First Tranche); 1,462 options on the 4th day of each month from 4 July 2026 through 4 April 2029 (34 monthly tranches); and 1,458 options on 4 May 2029 (Final Tranche). The options expire on 4 May 2033, subject to earlier termination as provided in the Option Agreement and the Plan.

	/s/ Wing Fung Alfred Siu	05/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did NewGenIvf Group (NIVF) report in this Form 4 filing?

NewGenIvf Group reported a grant of 56,851 stock options to its Chairman & CEO, Siu Wing Fung Alfred, under the 2024 Share Incentive Plan. These options allow him to acquire Class B Ordinary Shares at a nominal exercise price of US$0.0001 per share.

Who received stock options in NewGenIvf Group (NIVF) and in what amount?

Chairman & CEO Siu Wing Fung Alfred received 56,851 stock options to acquire Class B Ordinary Shares. The grant is part of NewGenIvf Group’s 2024 Share Incentive Plan and is held directly, as reflected in the Form 4 insider filing.

What is the exercise price of the NewGenIvf Group (NIVF) stock options granted?

The granted stock options have an exercise price of US$0.0001 per share. This very low strike price means the CEO can acquire Class B Ordinary Shares at a nominal cost when options vest, according to the 2024 Share Incentive Plan and option agreement.

How do the NewGenIvf Group (NIVF) CEO’s stock options vest?

The options vest over time: 5,685 options on 4 June 2026, then 1,462 options on the 4th of each month from July 2026 through April 2029, and 1,458 options on 4 May 2029, creating a structured, long-term vesting schedule.

When do the granted NewGenIvf Group (NIVF) stock options expire?

The CEO’s stock options expire on 4 May 2033, subject to earlier termination under the option agreement and plan terms. After this date, any unexercised options lapse and can no longer be used to acquire Class B Ordinary Shares of NewGenIvf Group.

How many NewGenIvf Group (NIVF) options does the CEO hold after this grant?

Following this grant, the CEO holds 56,881 stock options directly, as shown in the Form 4. This figure reflects his total derivative position in these options immediately after the award was made under the 2024 Share Incentive Plan.